Capricor Touts Long-Term Data from HOPE-2 Open Label Extension Duchenne Study

  Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today that the Company will present the three-year safety and efficacy results from its HOPE-2 open-label extension (OLE) study with lead asset deramiocel for treating Duchenne muscular dystrophy (DMD). The data will highlight the long-term, multi-modal benefits of deramiocel in a late-breaking poster presentation at the 29th Annual Congress of the World Muscle Society (WMS 2024), taking place October 8-12, 2024, in Prague, Czechia.

https://www.globenewswire.com/news-release/2024/10/04/2958371/0/en/Capricor-Therapeutics-to-Present-Long-Term-Data-from-HOPE-2-Open-Label-Extension-Study-at-2024-World-Muscle-Society-Congress.html